USA ANGELALIGN TECHNOLOGY CORP

In Program Year 2024, USA ANGELALIGN TECHNOLOGY CORP reported $99,951.12 in payments to 1,446 physicians and teaching hospitals across 1,446 individual transactions — an average of $69.12 per transaction and $69.12 per recipient. That total places USA ANGELALIGN TECHNOLOGY CORP at rank #1108 out of 1,797 companies in the CMS Open Payments database, representing 0.0% of all industry payments reported nationwide for the year. Payment volume at this scale is characteristic of manufacturers with broad prescriber engagement, active clinical research programs, or patented therapies generating ongoing royalty obligations.

The payment mix for USA ANGELALIGN TECHNOLOGY CORP spans 6 distinct categories defined by CMS — including general payments (consulting, speaker fees, meals, travel), research payments tied to clinical trials, and ownership or investment interests. The largest single category is "Food and Beverage" at $49.3K, accounting for 49.3% of the company's reported total and 1,383 transactions. This distribution matters because different payment types carry different regulatory and ethical implications: research funding supports clinical development, while general payments like meals and speaker fees have been studied for their correlation with prescribing patterns in peer-reviewed journals such as JAMA Internal Medicine.

Recipient concentration is another useful lens. The top 5 recipients of payments from USA ANGELALIGN TECHNOLOGY CORP received $0.00 combined — 0.0% of the company's total — with the remaining 100.0% distributed across the rest of the 1,446 recipients. A relatively distributed top-5 share suggests broader engagement across the prescriber community rather than concentration among a handful of high-value relationships. All figures above are drawn directly from the CMS Open Payments Public Use Files for PY2024 and are disclosed under the Physician Payments Sunshine Act; this page summarizes reported financial transfers and does not represent medical advice or judgment about individual prescribing decisions.